Main
Page 1 of 2

August 8, 2020

A Vaccine Challenge Trial?

Yesterday Richard Engel NBC National News, announced that scientists at Oxford's Jenner Institute in the UK are currently discussing a Challenge Trial of their Oxford AstraZeneca vaccine.  The vaccine is now in Phase 3 Clinical Trials in multiple countries.  There are many ethical arguments against a Challenge Trial in which all volunteers are vaccinated, and then several months later are given a measured, calculated dose of SARS-CoV-2 virus.  Oxford could enroll 40-60 volunteers and determine vaccine effectiveness in much less time. They say the Challenge Trial, which would be done in healthy 20 year olds, will have "minimal risks."  Vaccine Challenge Trials raise ethical questions, but were done previously for other pathogens. The problem in this instance, is the lack of effective treatment for those volunteers who do develop Covid-19?

Continue Reading Below: 

ChallengeSIZE.jpg 

Oxford AstraZeneca's standard Phase 3 randomized control trial is enrolling 30,000 volunteers - half will receive the vaccine and half will receive placebo.  No one including the patient will know what each volunteer receives until the end of the trial.  But if the volunteers aren't regularly exposed to the virus, it will take months to figure out the effectiveness of the vaccine.  Trial participants are told to lead their normal lives, but the trial will depend on them being exposed where virus infections are high.  The success of the vaccine is based on the number of cases of Covid-19 in the vaccinated group vs the placebo group.  In the US Moderna and Pfizer are also in Phase 3 testing with 30,000 volunteers.

  

August 5, 2020

CAUTION! WORRIED!

New York Times Aug 2:  "Scientists Worry About Political Influence Over Coronavirus Vaccine Project"  A horrifying article!  "Emergency Use Authorization" to make vaccine available in October, before the Phase 3 vaccine trial is complete, and that is required for FDA approval.  Continue reading....

EUA%20Part2SIZE.jpg 

 

This is long, but really important.  I am writing as a retired MD, who has experience with Clinical Trials for cancer treatment.  It is dangerous to make assumptions on Trial conclusions from incomplete data. 

There is great fear that there will be political pressure to release the front runner vaccines in October with an emergency use authorization (EUA).  I watched 6 hours of hearings by the House Energy and Commerce Subcommittee several weeks ago, and the 5 Vaccine Company representatives were asked over and over how they were going to insure the vaccines will be safe.  I watched an hour long interview of Dr. Stephen Hahn, by Dr. Howard Bauchner, last week.  Hahn is the FDA Commissioner and Bauchner is the editor of JAMA.  The Vaccine companies said that the Phase 3 Trials would not be rushed and safety compromised.  Dr.Hahn said that panels of vaccine scientists just worked on a set of standards that must be met in order to approve a vaccine - and this was done so any decision will be made based "only on the scientific data."

There was a very long article in the New York Times Aug 2nd, that was picked up by other news sites. They say there is a lot of political pressure to get a vaccine approved in October.  It says that if the FDA won't give "Emergency Use Authorization," the secretary of HHS in the White House can overrule his decision.  I recommend caution for the following reasons- and I usually take vaccines without worry.

1.  The two major US vaccines, Moderna-NIAID and Pfizer BioNtech, each began their phase 3 trials the last week in July. Moderna just published results of their Phase 1 Trial in NEJM (peer reviewed).  There were only 45 subjects vaccinated, evaluated, and reported.  They have not yet released their Phase 2 data.  I can't find any data from Pfizer as of today.  I assume they have completed Phase 1 and Phase 2 trials, although volunteers are usually followed for 1-2 years for late side effects.

2.  Moderna and Pfizer are part of Operation Warp Speed, and committed to test 30,000 volunteers in a Phase 3 trial.  Half of the volunteers will be vaccinated and half will get a placebo injection.  But no one will know who received which injection.  Volunteer enrollment just began( July 23 and 27).

3.  Each volunteer will get two doses, days 1 and 29 (Moderna) and days 1 and 21 Pfizer, so if they are enrolling volunteers beginning in August, the last volunteers enrolled will be getting their vaccinations in late August, September or even later.  By October those patients may not be followed long enough to adequately assess safety and efficacy! 

4.  The FDA will require that each vaccine will have a minimum of 50% efficacy (preferably >70%) in preventing Covid-19in the vaccinated group and acceptable adverse effects. Many tests to rate the immune response need to be done in specialized research labs and will take time.  These are blinded studies, and there are oversight committees set up who could stop the study if adverse effects are serious.

5.  If an EUA were granted due to political pressure, I wouldn't get that vaccine until the patients were all enrolled, followed for awhile, and preliminary results analyzed.  I want the vaccinated subjects to have at least 50% protection from Covid-19  when compared to the placebo group - AND side effects to be limited to injection site pain and flu-like symptoms. 

I'd also want to see careful review by other scientists.  The mumps vaccine set the speed record for vaccine development - 4 years. New technology made rapid vaccine development possible - both of these vaccines are made from the coronavirus spike protein genetic sequence and our cells make a spike protein which stimulates our immune system.  Older vaccines were made with inactive viruses or proteins of the virus.

 

 

 

 

 

August 1, 2020

EUA! PROTESTERS! No Emergency Use Approval!

Three Vaccine developers began their Phase 3 Randomized Controlled Trials in the last several weeks.  Each of them must enroll 30,000 healthy volunteers.  Half of the group will receive vaccine injections and the other half will receive a saline (salt water) injection as placebo.  Each volunteer will then be monitored for adverse events, and Covid-19.  Subgroups will also be tested for efficacy -both development of antibody titers and neutralizing antibodies that block virus proliferation.  In addition cellular immunity will be assessed by T helper cell activity.  No one will know what shot they received until the end of the trial.

Continue Reading Below:

EUASIZE.jpg 

Evidence of prevention of Covid-19 will be monitored in the treatment and placebo groups and results may depend on the activity of the virus where they are enrolling volunteers.  New York tests 50,000+ individuals each day, but the incidence of positive virus tests is only 1-1.5%.  If volunteers are vaccinated in the states with increasing infectivity, enrollment and protection in the vaccinated vs the placebo group may be faster.  Recently developed FDA guidelines for vaccine approval set the minimum at 50% protection by each vaccine for FDA approval.

BUT there may be political pressure to give "EMERGENCY USE APPROVAL" ("Pre-election Surprise) and then the government would be shortening the observation time for "rare, but significant" adverse effects to be seen.  The FDA commissioner this week said that his decisions will only be based on SCIENCE - and we have to hope that he is a man of his word.

 

July 29, 2020

Masks, Masks, Wear Your Mask

We are going to have to learn how to live with this virus until the population is vaccinated, and natural infection increases herd immunity to more than 70%.  Until we can be vaccinated, we MUST practice social distancing, hand washing, and mask wearing.  There is data to suggest that masks keep us from spreading the virus, AND they also limit the amount of virus that we breathe in.  When populations have protected themselves with masks they tend to have mild symptoms or are asymptomatic! See article link below.

On my morning walk I saw two store windows filled with these head mannequins and they had many different types of masks, in many different colors.  There even was a black mask covered in Swarovski crystals! Why do you think that the masks on the left have a narrow sliver hole over the nose? The store was still closed early in the AM, or I would have asked them.  I made masks for my husband and I, and our kids and grandkids that live in NYC.  As my back continues to improve I will make more.  I think we are destined to be wearing masks until 2021.  I love the pattern I used, and will also include a link at the bottom of this post.  Read more below.

Masks%20MasksSIZE.jpg 

This week two companies began Phase 3 vaccine trials.  They each need 30,000 healthy volunteers to determine if the vaccinated and placebo groups have a significant difference in Covid-19infection. Research Labs will also be measuring antibody titers and T cell responses in a cohort of the subjects.  In order to have a definitive answer, infectivity in the geographic area must be high enough to make people sick - the FDA approval requires 50% protection in the vaccinated group - at a minimum.  .

The "In Press" paper re: Masks is embedded in this article.  This is not a clinical trial - just a collection of observations from the pandemic by a well trained infectious disease MD and public health expert.
 
I searched lots of mask patterns - and loved this video and pattern.  I insert the elastic so it goes around my neck and head.  Fits each of my family members better than other fabric masks they have - some like ear loops and some prefer the neck-head configuration.  Cut and paste the link into your browser.
https://www.youtube.com/watch?v=1V3SLUHIJ5A 

July 25, 2020

Can Antibodies Be Used to Treat Covid-19?

When you transfuse antibodies into patients, you develop "passive, instead of natural immunity."  During the 1918 flu pandemic, patients who recovered from influenza donated blood so their antibodies could be transfused into other critically ill patients.  More recently, "convalescent plasma" from recovered Ebola patients was given to other patients.  Randomized control trials (RCT) are being done to test "convalescent plasma" for Covid-19 patients, but in addition MONOCLONAL ANTIBODIES are being developed from blood obtained from recovered patients.   Read about them below the collage.

 MoAb%20InfusionSIZE.jpg

Patients who have recovered from Covid-19 have naturally occurring immunity against all parts of the SARS-CoV-2 virus.  Their antibodies and immune cells are being studied, and the strongest neutralizing antibodies (which stop viral replication), are used to develop monoclonal antibodies which can be produced in large quantities.  This technology was first developed in the 1970s and is now being used to create many types of therapy, including cancer drugs.  In the classic method, cells which are producing antibodies are fused with a specific clone of antibody producing cells that can be grown in culture.  This clone becomes a protein factory which makes just one potent neutralizing antibody.  There are many monoclonal antibodies being made to SARS-CoV-19 and at least 3 are in early clinical trials.  Passive immunity with monoclonal antibodies is only effective for weeks to a month+, but when administered they can change the course of critically ill patients.  You can usually recognize monoclonal antibodies that are FDA approved because their names end with "ab."

<< 1 2